Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Equity: 2021-2025

Historic Return on Equity for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to 1.55%.

  • Xeris Biopharma Holdings' Return on Equity fell 110.00% to 1.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.55%, marking a year-over-year decrease of 110.00%. This contributed to the annual value of 3.01% for FY2024, which is 626.00% up from last year.
  • Xeris Biopharma Holdings' Return on Equity amounted to 1.55% in Q3 2025, which was up 31.93% from 1.18% recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Return on Equity ranged from a high of 42.68% in Q4 2023 and a low of -7.06% during Q3 2023.
  • For the 3-year period, Xeris Biopharma Holdings' Return on Equity averaged around 4.66%, with its median value being 1.55% (2025).
  • In the last 5 years, Xeris Biopharma Holdings' Return on Equity spiked by 4,457bps in 2023 and then tumbled by 4,079bps in 2024.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Return on Equity stood at -2.65% in 2021, then skyrocketed by 76bps to -1.89% in 2022, then surged by 4,457bps to 42.68% in 2023, then crashed by 4,079bps to 1.89% in 2024, then tumbled by 110bps to 1.55% in 2025.
  • Its Return on Equity stands at 1.55% for Q3 2025, versus 1.18% for Q2 2025 and 1.39% for Q1 2025.